Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grade B-cell non-Hodgkin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Extranodal Marginal Zone Lymphoma
• Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Lymphoplasmacytic Lymphoma
• Marginal Zone Lymphoma
• Marginal Zone Lymphoma Various Subtypes
• Mucosa-associated Lymphoid Tissue Lymphoma
• Nodal Marginal Zone Lymphoma
• Richter Syndrome
• Small Lymphocytic Lymphoma
• Splenic Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Idelalisib (idelalisib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2023-03-21